Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid® Expanding Treatment of Severe Burns to Children Age One to Four
YAVNE, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the European Medicines Agency (EMA) has endorsed the extension of the Children Innovative Debridement Study (CIDS) popu...
View HTML
Toggle Summary MediWound Reports Final Positive Results of Phase 2 Clinical Trial of EscharEx for the Debridement of Chronic and Hard-to-Heal Wounds
YAVNE, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces final positive results from the Company's second Phase 2 clinical trial evaluating EscharEx® for debridement of dead or...
View HTML
Toggle Summary MediWound Granted U.S. Patent for MWPC003 for the Treatment of Connective Tissue Diseases
YAVNE, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the United States Patent and Trademark Office (USPTO) has issued patent Number 9,511,126 with claims related to the Com...
View HTML
Toggle Summary Abstract Highlighting NexoBrid® in Burn Mass Casualties Awarded "Best Poster" at the International Disaster and Military Medicine Conference
YAVNE, Israel, Nov. 18, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBrid® in the management of burns in mass casualty incidents was selecte...
View HTML
Toggle Summary MediWound Reports Third Quarter 2016 Financial Results
YAVNE, Israel, Nov. 14, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and nine months ended September 30, 2016. Highlights of the third quarter of 2016 include...
View HTML
Toggle Summary MediWound to Host Third Quarter 2016 Financial Results Conference Call on November 14, 2016 at 8:30 a.m. Eastern Time
YAVNE, Israel, Nov. 04, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three and nine months ended September 30, 2016, at 7:00 a.m. E...
View HTML
Toggle Summary MediWound to Present at the Credit Suisse 25th Annual Healthcare Conference
YAVNE, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Credit Suisse 25th Annual Healthcare Conference taking place from November 6...
View HTML
Toggle Summary MediWound to Present at 11th Annual Wells Fargo Healthcare Conference
YAVNE, Israel, Aug. 26, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 11th Annual Wells Fargo Securities Healthcare Conference taking place from S...
View HTML
Toggle Summary MediWound's NexoBrid and EscharEx to be Featured at International Society for Burn Injuries 2016
Multiple oral and poster presentations highlight NexoBrid's and EscharEx' innovative, effective and fast enzymatic debriding of severe burns and chronic wounds
View HTML
Toggle Summary MediWound Reports Second Quarter 2016 Financial Results
Conference call begins today at 8:30 a.m. Eastern time
View HTML